ACIU

AC Immune SA

2.29

USD

-0.15

-6.15%

Nov 10, 15:59 UTC -5

Closed

After-Market

2.29

0.00

-0.22%

AC Immune SA (ACIU) Earnings

ACIU Earnings Reports

Positive Surprise Ratio

ACIU beat 25 of 40 last estimates.

63%

Next Report

Date of Next Report

Mar 11, 2027

Estimate for Q4 26 (Revenue/ EPS)

$1.98M

-$0.10

Implied change from Q3 26 (Revenue/ EPS)

-39.10%

-23.08%

Implied change from Q4 25 (Revenue/ EPS)

+484.46%

-23.08%

AC Immune SA earnings per share and revenue

On Nov 04, 2026, ACIU reported earnings of -0.13 USD per share (EPS) for Q3 26, beating the estimate of -0.16 USD, resulting in a 20.83% surprise. Revenue reached 3.24 million, compared to an expected 206.60 thousand, with a 1470.18% difference. The market reacted with a +9.57% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.10 USD, with revenue projected to reach 1.98 million USD, implying an decrease of -23.08% EPS, and decrease of -39.10% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were AC Immune SA's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, AC Immune SA reported EPS of -$0.13, beating estimates by 20.83%, and revenue of $3.24M, 1470.18% above expectations.

How did the market react to AC Immune SA's Q3 2026 earnings?

The stock price moved up 9.57%, changed from $2.09 before the earnings release to $2.29 the day after.

When is AC Immune SA expected to report next?

The next earning report is scheduled for Mar 11, 2027.

What are the forecasts for AC Immune SA's next earnings report?

Based on -- analysts, AC Immune SA is expected to report EPS of -$0.10 and revenue of $1.98M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.